Market Executive Summary

REPORT HIGHLIGHT
The genitourinary therapeutics Market is estimated to represent a global market of USD 30.2 billion by 2028 with growth rate of 1.2%. The market covers the analysis of the commercial or pipeline therapeutics that can be used for genital and urinary organ treatment. Conditions such as Glomerulonephritis, Hemolytic uremic syndrome, Polycystic kidney disease and Hydronephrosis may damage kidney. Thus, it is advisable to treat these conditions at right time.
Growing demand for genitourinary therapeutics in developed as well as developing regions drives the market growth. Emerging and leading genitourinary therapeutics are studies under the scope of this research study. Furthermore, undergoing clinical trials and patents are studies during the market estimation.Constant increase in number of pipeline therapeutics in this market segment boost the market growth to large level.
For example, in September 2017, Bristol-Myers Squibb collaborated with Nektar Therapeutics to assess the efficacy of NKTR-214 and Opdivo (nivolumab) in bladder cancer. Additionally, during the same time period, the company announced the validation of the Type II variation application for Opdivo (nivolumab) in the treatment of advanced bladder cancer by the European Medicines Agency.
The global market is categorized in terms of different indications like prostate cancer, benign prostatic hyperplasia, ovarian cancer, cervical cancer, renal cancer, erectile dysfunction, Urinary incontinence & overactive bladder, sexually transmitted diseases and others. In terms of revenue estimation, prostate and renal cancer was the market leading player as of 2017. Among which, renal cancer captured almost 26.11% share of the global revenue in 2017 whereas prostate cancer accounted for more than 20% share. Rising disease incidence in these segments coupled with continuous increase in therapeutic demand among patients drives the market growth in forecast period.
Based on products, the market studied in terms of anti-infective, urological, hormonal therapy drugs, and others. Hormonal therapy and urological segment is widely accepted products among the end user due to its high efficiency and cost effectiveness. Thereby, these segment captured largest revenue share, more than USD 12.0 billion of the global market.
Regionally, North American countries dominated the global market with the share of over 40% throughout the study period. Research and development initiatives by domiciled key players coupled with rising prevalence of genital and urinary diseases augment the overall revenue growth. Hormonal therapy drugs such as Casodex(Bicalutamide), Lupron(Leuprolide), Zoladex(Goserelin), Zytiga(Abiraterone), Xtandi(Enzalutamide), Eligard(Leuprolide) and Gonax(degaralix) widely used in these regions which helps the market to grow steadily.
On contrary, Asia Pacific region recorded highest CAGR of 6.2% during the forecast period. Increasing awareness level coupled with improving healthcare infrastructure supported the growth in Asia and Pacific countries like India, China and Japan. Also, increasing gynaecological diseases in developing regions will further boost the demand for drugs such as Doxil(Doxorubicin), Avycaz, Estrace and Estring, further support the market growth.
The market size and forecast for each segment has been provided for the period 2014 to 2028, considering 2017 as the base year. The report also provides the compounded annual growth rate (% CAGR) for the forecast period 2017 to 2028 for every reported segment.
The years considered for the study are:
Historical Year ? 2014 & 2017
Base Year ? 2017
Estimated Year ? 2017
Projected Year ? 2028
TARGET AUDIENCE
Hospitals
Manufacturers
Traders, Distributors, And Suppliers
Government and Regional Agencies and Research Organizations
Consultants
Distributors
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
MARKET, BY INDICATION
Prostate cancer
Benign prostatic hyperplasia
Ovarian cancer
Cervical cancer
Renal cancer
Erectile dysfunction
Urinary incontinence & overactive bladder
Sexually transmitted diseases
Others
MARKET, BY PRODUCTS
Anti-infective
Urological
Hormonal therapy drugs
Others
MARKET, BY REGION
North America
Europe
Asia Pacific
Rest of the World
MARKET,BY COUNTRY
Further Breakdown of The North America Market
U.S.
Canada
Further Breakdown of The Europe Market
Germany
France
Rest of Europe
Further Breakdown of The APAC Market
India
China
Rest of APAC
Further Breakdown of The Rest of the World Market
Middle East and Africa
Latin America